$0.11 2.4%
EYEN Stock Price vs. AI Score
Data gathered: November 23

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Eyenovia (EYEN)

Analysis generated September 20, 2024. Powered by Chat GPT.

Eyenovia, Inc. is a clinical-stage biopharmaceutical company specializing in eye care. The company focuses on developing a portfolio of advanced ophthalmic therapeutics based on its proprietary microdose array print (MAP) technology. This technology aims to enhance the safety and efficacy of ophthalmic drugs, representing a significant innovation in the industry.

Read full AI stock Analysis

Stock Alerts - Eyenovia (EYEN)

company logo Eyenovia | November 22
Price is up by 6.6% in the last 24h.
company logo Eyenovia | November 21
Price is up by 8.2% in the last 24h.
company logo Eyenovia | November 20
Price is down by -14.7% in the last 24h.
company logo Eyenovia | November 19
Price is up by 8.1% in the last 24h.

About Eyenovia

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology.


Eyenovia
Price $0.11
Target Price Sign up
Volume 29,950,000
Market Cap $9.1M
Year Range $0.09 - $1.59
Dividend Yield 0%
Analyst Rating 0% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '241,600130,000-130,000-7.9M00.000
Q2 '2423,000490,000-470,000-11M-8.5M-0.210
Q1 '245,0005,000-200,000-11M-7.9M-0.230
Q4 '232,6002,600-680,000-8M-7.2M-0.180
Q3 '231,20013,000-12,000-7.3M-6.5M-0.180

Insider Transactions View All

Rowe Michael M filed to buy 109,998 shares at $0.5.
August 28 '24
Rowe Michael M filed to buy 82,927 shares at $0.6.
August 27 '24
Grant Stuart M. filed to buy 10,914,153 shares at $0.7.
July 3 '24
Grant Stuart M. filed to buy 5,430,715 shares at $1.
March 28 '24
Grant Stuart M. filed to buy 5,330,715 shares at $1.2.
March 20 '24

What is the Market Cap of Eyenovia?

The Market Cap of Eyenovia is $9.1M.

What is the current stock price of Eyenovia?

Currently, the price of one share of Eyenovia stock is $0.11.

How can I analyze the EYEN stock price chart for investment decisions?

The EYEN stock price chart above provides a comprehensive visual representation of Eyenovia's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Eyenovia shares. Our platform offers an up-to-date EYEN stock price chart, along with technical data analysis and alternative data insights.

Does EYEN offer dividends to its shareholders?

As of our latest update, Eyenovia (EYEN) does not offer dividends to its shareholders. Investors interested in Eyenovia should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Eyenovia?

Some of the similar stocks of Eyenovia are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.